本研究旨在探讨一项定制分子检测能否在肠化生 (IM) 患者中识别出发展为胃癌风险极高的患者亚组。研究人员假设，分子检测阳性组的异型增生及胃癌病例发生率将显著高于分子检测阴性组。此类检测有望指导临床医生更好地管理

适应症：Stomach Neoplasm

入组条件

The subject is above 50 years old or turns 50 years old in the year of recruitment
The subject is below 76 years old in the year of recruitment
The subject is willing and able to provide signed and dated patient informed consent form indicating that they has been informed of all pertinent aspects of the study

The subject who has bleeding disorders, such as haemophilia, in whom biopsies are contraindicated.
The subject with a personal history of high-grade dysplasia or GC.
The subject with liver cirrhosis.
The subject with previous total or partial gastrectomy.
The subject with severe co-morbid illness, such as end-stage renal failure (ESRF), congestive cardiac failure (CCF), severe osteoarthritis (OA), and rheumatoid arthritis (RA) requiring long-term non-steroidal anti-inflammatory drug (NSAID) therapy.
The subject with other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results and in the judgement of the investigator would make the subject unsuitable for entry into the study.
The subject on regular anti-coagulant prophylaxis such as warfarin must be able to undergo a 5-day washout period before each gastroscopy. The subject on aspirin, ticlopidine and clopidogrel must be able to undergo a one-week washout period before each gastroscopy. The subject's physician or study co-investigator will exercise their clinical judgement to ensure subject's safety.
The subject is unwilling or unable to provide signed informed consent.

入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。

用于高风险肠化生患者风险分层的分子检测验证（GCEP2 研究）